Peptide drug discovery and development : translational research in academia and industry

著者

    • Castanho, Miguel
    • Santos, Nuno C.

書誌事項

Peptide drug discovery and development : translational research in academia and industry

edited by Miguel Castanho and Nuno C. Santos

Wiley-VCH, c2011

  • : print

大学図書館所蔵 件 / 全3件

この図書・雑誌をさがす

注記

Includes bibliographical references and index

内容説明・目次

内容説明

Filling a real knowledge gap, this handbook and ready reference is both modern and forward-looking in its emphasis on the "bench to bedside" translational approach to drug development. Clearly structured into three major parts, the book stakes out the boundaries of peptide drug development in the preclinical as well as clinical stages. The first part provides a general background and focuses on the characteristic strengths and weaknesses of peptide drugs. The second section contains five cases studies of peptides from diverse therapeutic fields, and the lessons to be learned from them, while the final part looks at new targets and opportunities, discussing several drug targets and diseases for which peptide drugs are currently being developed.

目次

Preface PART I: The Academia - Market Bouncing of Peptide Drugs - Challenges and Strategies in Translational Research with Peptide Drugs PEPTIDES AS LEADS FOR DRUG DISCOVERY Introduction Overview of Process for Transforming Peptides to Peptidomimetics HCMV Protease HCV Protease Herpes Simplex Virus Renin HIV Conclusions MARKETING ANTIMICROBIAL PEPTIDES: A CRITICAL ACADEMIC POINT OF VIEW Introduction Basic Research: Antimicrobial Peptides Patents Potential Applications of AMPs Technology Transfer: Valorization, Licensing, or Spin-Off Creation Spin-Off Creation: An Academic Point of View ORAL PEPTIDE DRUG DELIVERY: STRATEGIES TO OVERCOME CHALLENGES Introduction Challenges Associated with Oral Petide Delivery Strategies to Overcome the Barriers of the Gastrointestinal Tract Conclusions RATIONAL DESIGN OF AMPHIPATHIC ALPHA-HELICAL AND CYCLIC BETA-SHEET ANTIMICROBIAL PEPTIDES: SPECIFICITY AND THERAPEUTIC POTENTIAL Introduction to Antimicrobial Peptides Antimicrobial and Hemolytic Activities of Amphipathic Alpha-Helical Antimicrobial Peptides: Mechanisms and Selectivity Structure-Activity Relationship Studies of Amphipathic Alpha-Helical and Cyclic Beta-Sheet Antimicrobial Peptides: Optimization of Pathogen Selectivity and Prevention of Host Toxicity Commercialization of Antimicrobial Peptides Therapeutic Potential CONOTOXIN-BASED LEADS IN DRUG DESIGN Introduction Conotoxin Classification and Targets Conotoxins as Drug Leads Conclusions PLANT ANTIMICROBIAL PEPTIDES: FROM BASIC STRUCTURES TO APPLIED RESEARCH Introduction The Diversity of Plant Antimicrobial Peptides: Focusing on Tissue Localization and Plant Species Distribution Possible Structural Folds Found in Plant AMPs to Date New Biotechnological Products Produced from Plant Peptides PART II: Peptide Drugs' Translational Tales - Peptide Drugs Before, Through and After Industry Pipelines OMIGANAN PENTAHYDOCHLORIDE: A NOVEL, BROAD-SPECTRUM ANTIMICROBIAL PEPTIDE FOR TOPICAL USE Omiganan: A Novel Anti-Infective Agent for Topical Indications Structure and Mechanism of Action Spectrum of Activity Preclinical Efficacy Studies Preclinical Toxicology Studies Clinical Studies Conclusions TURNING ENDOGENOUS PEPTIDES INTO NEW ANALGESICS: THE EXAMPLE OF KYOTORPHIN DERIVATIVES Introduction Peptides as Future Drug Candidates Central Nervous System Anagesic Peptides Endogeneous Opioid Systems Strategies to Deliver Analgesic Peptides to the Brain Development of New Opioid-Derived Peptides Kyotorphin - The Potential of an Endogenous Dipeptide New KTP Derivatives Assessing BBB Permeability with Peptide - Membrane Partition Studies Kyotorphines: Partition to the Membrane and Enhanced Analgesic Activity Academia and Pharmaceutical Industry: Friends or Foes? THE DEVELOPMENT OF ROMIPLOSTIM - A THERAPEUTIC PEPTIBODY USED TO STIMLATE PLATELET PRODUCTION Introduction Thrombopoietin and c-Mpl Discovery and Optimization of Romiplostim Pharmacodynamics (PD) and Pharmacokinetics (PK) of Romiplostim A Brief ITP Primer Romiplostim Clinical Data Safety and Other Insights Gained from Romiplostim Design and Development HIV VS HIV: TURNING HIV-DERIVED PEPTIDES INTO DRUGS Introduction HIV-1 Envelope Protein HIV Entry and Its Inhibition HIV-1 Fusion Inhibitors: From Bench to Clinical Administration New Strategies for Creating New HIV Fusion Inhibitor Peptides Drug-Resistance and Combination Therapy Concluding Remarks SIFUVIRTIDE, A NOVEL HIV-1 FUSION INHIBITOR Ideal Drug Target HIV-1 pg41 Structure-Based Drug Design of Sifuvirtide High Potency of Sifuvirtide Limited Drug Resistance Enhancement of the Efficiency of Sifuvirtide by Biomembrane Selectivity Pharmacokinetics of Sifuvirtide with Long Half-Life Stratification of Monotherapy 20 mg Sifuvirtide Once Daily vs. 100 mg T10 Twice Daily Conclusions and Discussion PART III: Whither Peptide Drugs? Peptides Shaping the Future of Drug Development ENDOGENOUS PEPTIDES AND THEIR RECEPTORS AS DRUG DISCOVERY TARGETS FOR THE TREATMENT OF METABOLIC DISEASE Centrally Secreted Neuropeptide Systems Peripherally Secreted Neuropeptides Summary TRANSLATION OF MOTILIN AND GHRELIN RECEPTOR AGONISTS INTO DRUGS FOR GASTROINTESTINAL DISORDERS Introduction Motilin and Ghrelin Receptor Agonists Under Development Translational Value of Preclinical Assays Clinical Translation: Selecting the "Right" Patient Population Clinical Development of Motilin and Ghrelin Receptor Agonists Conclusions OF MICE AND MEN: TRANSLATIONAL RESEARCH ON AMYLIN AGONISM Overview of Amylin Physiology Pramlintide: An Amylin Agonist Amylin Agonism: Translational Research in Insulin-Dependent Diabetes Amylin Agonism: Translational Research in Obesity PEPTIDES AND POLYPEPTIDES AS IMMUNOMODULATORS AND THEIR CONSEQUENTIAL THERAPEUTIC EFFECT IN MULTIPLE SCLEROSIS AND OTHER AUTOIMMUNE DISEASES Introduction Peptides as Antigens and Vaccines Peptides as Immunomodulators Development of Copolymer 1 - A Polypeptide Immunomodulator Drug for the Treatment of Multiple Sclerosis Additional Immunomodulatory Peptides as Drug Candidates Summary and Concluding Remarks DEVELOPMENT OF ANTIBODY FRAGMETNS FOR THERAPEUTIC APPLICATIONS Antibodies Conclusions

「Nielsen BookData」 より

詳細情報

ページトップへ